

# Activity Information and Show Notes

As a reminder to obtain CME credit for this activity you must complete and return the evaluation and posttest. This activity is credit eligible for up to **1 AMA PRA Category 1 CME credit™** for both physicians and any clinical staff where their boards recognize ACCME CME credits. Please review the instructions, activity information and show notes with references listed below.



*Be "in-the-know" with a multidisciplinary podcast series aimed at improving practice and patient care.*



## “CBD Updates”

with hosts

**Susan C. Zwiebel, M.D.**  
LM Occupational Health

**Mindi L. Wells, Esq.**  
Attorney at Law

Certified Civil Rights Investigator (ATIXA)

Season 1, Episode 2: “CBD Updates”

### INSTRUCTIONS TO OBTAIN EDUCATION CREDITS

- 1) Click on the link provided in the podcast release email or access the podcast on the LMH CME website at <https://www.lmhealth.org/Login>. Login using your email and password.
- 2) Listen to the podcast.
- 3) Complete the podcast evaluation, attestation and posttest form. Please note, you must score a 70% or higher on the posttest.
- 4) **Email the evaluation, attestation and posttest form to [JAdamson@lmhealth.org](mailto:JAdamson@lmhealth.org) or print, complete and fax to (220) 564-4012. You must complete this step to obtain CME credit for listening.**
- 5) Upon receipt of your evaluation, attestation and posttest form, you will be awarded your CME credit and this will be added to your LMH CME transcript.

### DESCRIPTION:

Join us for Episode two of LMH CME podcast series “In The Know”. Episode two focuses on “CBD Updates” with hosts Suzan C. Zwiebel, LM Occupational Health and employment attorney Mindi L. Wells, Esq.

**SERIES NAME**

Season 1: "In The Know" LMH CME  
Episode 2: "CBD Updates"  
55 minutes and 48 seconds

**DATE**

April 23, 2021

**EPISODE TITLE**

"CBD Updates"

**PRESENTERS**

Susan C. Zwiebel, M.D.  
Mindi L. Wells, Esq.

**OBJECTIVES**

Listeners of this podcast will be able to know or do at the conclusion of this learning activity:

- Identify the difference between hemp, CBD and THC
- Analyze CBD safety concerns
- Report if CBD and other CBD products cause a positive drug screen for delta-9-THC

**SHOW NOTES AND RESOURCE LINKS****REFERENCES****Charlottes' Web Medical Cannabis**

<https://www.youtube.com/watch?v=oxrKyjeCITk>

CNN documentary on Charlotte's Web, medical marijuana treating seizure disorders  
7 minutes 44 seconds

Alsherbiny, M., & Li, C. (2018). Medicinal cannabis—Potential drug interactions. *Medicines*, 6(1), 3.  
doi:10.3390/medicines6010003

Baum, S. (2021, March 23). Re: Marijuana question [E-mail]

Bonn-Miller, M. O., Loflin, M. J. E., Thomas, B. F., Marcu, J. P., Hyke, T., & Vandrey, R. (2017). Labeling accuracy of Cannabidiol extracts sold online. *JAMA*, 318(17), 1708. doi: 10.1001/jama.2017.11909

Brady, K. T. (2020). Medical marijuana: Putting the cart before the horse. *American Journal of Psychiatry*, 177(7), 570-571. doi:10.1176/appi.ajp.2020.20050648

Brown, J., & Winterstein, A. (2019). Potential adverse drug events and drug–drug interactions with medical and consumer Cannabidiol (CBD) use. *Journal of Clinical Medicine*, 8(7), 989.  
doi:10.3390/jcm8070989

Carlini, E. A., & Cunha, J. M. (1981). Hypnotic and antiepileptic effects of cannabidiol. Retrieved November 12, 2019, from <https://www.ncbi.nlm.nih.gov/pubmed/7028792>.

Commissioner, O. of the. (2019, October 16). FDA Regulation of Cannabis and Cannabis-Derived Products: Q&A. Retrieved November 12, 2019, from [https://www.fda.gov/news-events/public-health-focus/fda-regulation-cannabis-and-cannabis-derived-products-including-cannabidiol-cbd#dietary\\_supplements](https://www.fda.gov/news-events/public-health-focus/fda-regulation-cannabis-and-cannabis-derived-products-including-cannabidiol-cbd#dietary_supplements).

Dahlgren, M. K., Sagar, K. A., Lambros, A. M., Smith, R. T., & Gruber, S. A. (2021). Urinary tetrahydrocannabinol after 4 weeks of a full-spectrum, high-cannabidiol treatment in an open-label clinical trial. *JAMA Psychiatry*, 78(3), 335. doi:10.1001/jamapsychiatry.2020.3567

Drug Scheduling. (n.d.). Retrieved October 3, 2019, from <https://www.dea.gov/drug-scheduling>.

EPIDIOLEX® (cannabidiol) CV. (2019). Retrieved November 19, 2019, from <https://www.epidiolex.com/>.

Establishment of a Domestic Hemp Production Program. (2019, October 31). Retrieved November 21, 2019, from <https://www.federalregister.gov/documents/2019/10/31/2019-23749/establishment-of-a-domestic-hemp-production-program>.

FDA Regulation of Cannabis and Cannabis-Derived Products: Q&A. (2019, November 13). Retrieved November 22, 2019, from <https://www.fda.gov/news-events/public-health-focus/fda-regulation-cannabis-and-cannabis-derived-products-including-cannabidiol-cbd>.

Flegel, R. R. (2019, July 24). Federal agency drug program coordinators, Federal medical review officers, and federal partners. Substance Abuse and Mental Health Services Administration. Retrieved March 24, 2021, from <https://www.samhsa.gov/sites/default/files/workplace/hemp-products-csap-memo-072419.pdf>

Gottlieb, S. (2018, December 20). Statement from FDA Commissioner Scott Gottlieb, M.D., on signing of the Agriculture Improvement Act and the agency's regulation of products containing cannabis and cannabis-derived compounds. Retrieved November 22, 2019, from <https://www.fda.gov/news-events/press-announcements/statement-fda-commissioner-scott-gottlieb-md-signing-agriculture-improvement-act-and-agencys>.

GovTrack.us. (2021). S. 2227 — 116th Congress: MORE Act of 2019. Retrieved from <https://www.govtrack.us/congress/bills/116/s2227>

Guidance on Products Derived from Hemp. (2019, July). Retrieved November 22, 2019, from <https://www.pharmacy.ohio.gov/Documents/Pubs/Special/MedicalMarijuanaControlProgram/Guidance on Products Derived from Hemp.pdf>.

Gurley, B. J., Murphy, T. P., Gul, W., Walker, L. A., & ElSohly, M. (2020). Content versus label claims in cannabidiol (CBD)-Containing products obtained from commercial outlets in the state of Mississippi. *Journal of Dietary Supplements*, 17(5), 599-607. doi:10.1080/19390211.2020.1766634

MarketNewsUpdates.com. (2018, August 21). Robust Growth in Cannabidiol (CBD) and Hemp Market Fueling Strong Optimistic Outlook. Retrieved November 12, 2019, from <https://www.prnewswire.com/news-releases/robust-growth-in-cannabidiol-cbd-and-hemp-market-fueling-strong-optimistic-outlook-854350949.html>.

Medical Marijuana and Its Impact on BWC. (2018, August). Retrieved December 24, 2019, from <https://www.bwc.ohio.gov/downloads/blankpdf/medmarijuanaimpact.pdf>.

More CBD Oil Controversy. (2019, September 13). More CBD Oil Controversy.

NORML. (2020, September 14). Ohio local decriminalization. Retrieved March 23, 2021, from <https://norml.org/laws/local-decriminalization/ohio-local-decriminalization/>

Nunnari, M. C. (2019, November 25). No Medical Marijuana in Ohio BWC's Drug-Free Workplace. Retrieved December 24, 2019, from <https://www.laboremploymentlawnavigator.com/>

Quest Diagnostics. CLIA WAIVED express results integrated multi-drug screen cup. (2009). [http://www.questdiagnostics.com/dms/Documents/Employer-Solutions/Package-inserts/pkg\\_insert\\_clia\\_waived/pkg\\_insert\\_clia\\_waived.pdf](http://www.questdiagnostics.com/dms/Documents/Employer-Solutions/Package-inserts/pkg_insert_clia_waived/pkg_insert_clia_waived.pdf). Accessed August 26, 2020.

Riegelman. (2018). Public Health 101. Jones and Bartlett Learning.

Rugaber, C. (2018, May 6). Businesses more chill about pot. *Newark Advocate*, p. 1B.

Sirven, J. I., Garcia, P., & Dashe, J. F. (2018, December 20). Evaluation and management of drug-resistant epilepsy. Retrieved November 19, 2019, from <https://www.uptodate.com/>

Schultz, T. (2020, August 1). Cannabis and workers: The need for more research. *MRO Alert*, 31, 18-20.

Shults, T. (2019, October). The Untenable Legal Status of CBD, THC and Drug Testing. Retrieved December 23, 2019, from <https://www.aamro.com/>.

Schultz, T. (2020, November 1). High CBD treatments and urine drug tests. *MRO Alert*, 31, 2-3.

Spindle, T. R., Cone, E. J., Kuntz, D., Mitchell, J. M., Bigelow, G. E., Flegel, R., & Vandrey, R. (2019). Urinary pharmacokinetic profile of Cannabinoids following administration of vaporized and Oral cannabidiol and vaporized CBD-dominant cannabis. *Journal of Analytical Toxicology*, 44(2), 109-125. doi:10.1093/jat/bkz080

Swart, J. L. (2019, August 29). DOT "Medical Marijuana" Notice. Retrieved October 3, 2019, from <https://www.transportation.gov/odapc/medical-marijuana-notice>.

Title 21 Code of Federal Regulations. (2019, July 17). Retrieved October 3, 2019, from [https://www.deadiversion.usdoj.gov/21cfr/cfr/1308/1308\\_11.htm](https://www.deadiversion.usdoj.gov/21cfr/cfr/1308/1308_11.htm).

Wallace, A. (2019, November 1). Hemp is legal. Here comes the tricky part. Retrieved November 21, 2019, from <https://www.cnn.com/2019/11/01/business/usda-domestic-hemp-program/index.html>.

VanDolah, H. J., Bauer, B. A., & Mauck, K. F. (2019). Clinicians' guide to cannabidiol and hemp oils. *Mayo Clinic Proceedings*, 94(9), 1840-1851. doi:10.1016/j.mayocp.2019.01.003

## **PLANNING COMMITTEE**

Craig Cairns, M.D., LMH Medical Education Planning Committee Chair, Activity Approval and Independent Reviewer

Susan Swiebel, M.D., Medical Director Occupational Health, faculty and planner

Mindi Wells, Esq., Wells Law, faculty and planner

Jessica Adamson, CME Coordinator, Planning Member

## **DISCLOSURE STATEMENT**

No one in a position to control content has any relationships with commercial interests.

## **COMMERICAL SUPPORT**

Licking Memorial Hospital has not received any commercial support for this activity.

## **CME INFORMATION**

**Accreditation:** Licking Memorial Hospital is accredited by the Ohio State Medical Association to provide continuing medical education for physicians.

**Designation:** Licking Memorial Hospital designates this **enduring material** activity for a maximum of **1 AMA PRA Category 1.0 Credit™**. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

**Enduring Material Expiration:** This enduring material activity is valid from 5/18/21 – 5/18/23 and will be reviewed by the CME Planning Committee annually for content and validity.

*Music courtesy of Pixabay, royalty free music at <https://pixabay.com/music/>. "Hope", creator Tim Moor.*